Determination of functional kidney volume by single-photon emission computed tomography in patients with insulin-dependent diabetes mellitus.

Functional parenchymal kidney volume was determined by single-photon emission computed tomography (SPECT) for 99mTc-dimercaptosuccinic acid (DMSA) using a rotating gamma camera in phantom experiments and in patients with insulin-dependent diabetes mellitus (IDDM). The results from the patient examinations were corrected according to the phantom studies and were thereafter set in relation to renal haemodynamics, blood pressure, and urinary albumin excretion. Functional parenchymal kidney volume was significantly greater in diabetic patients compared to that of 11 healthy controls (P < 0.003). Urinary albumin excretion was increased and glomerular filtration rate (GFR) per renal parenchymal volume significantly less in patients with a duration of diabetic disease of more than 15 years compared to patients with shorter duration of disease (P < 0.03 and P < 0.05 respectively). Diabetic patients with a GFR of more than 120 ml/min had greater renal parenchymal volume than patients with lower GFR (P < 0.02). Patients with increased GFR, renal plasma flow (RPF), renal blood flow, or filtration fraction had significantly greater functional parenchymal volume than the healthy subjects (P < 0.01 for all comparisons). We conclude that by application of SPECT for DMSA we were able to show that IDDM patients have greater renal parenchymal volumes than healthy subjects. GFR/kidney volume was increased in IDDM patients with a duration of disease of < 15 years compared to patients with long-standing diabetes. The SPECT technique seems suitable for prospective long-term follow-up studies of functional kidney volume in IDDM patients.     

Bacterial superantigen enhances cytokine production by T-helper lymphocyte subset-2 cells and modifies glomerular lesions in experimental immunoglobulin a nephropathy

Background The purpose of this study was to examine the effects of bacterial suporantigens, which can derange the immune response and contribute to the renal lesions of immunoglobulin A (lgA) nephropathy. Methods Twenty-five micrograms of a bacterial superantigen, staphylococcal enterotoxin B (SEB), was injected into IgA nephropathy-prone ddY mice intrathymically when they reached 6 weeks of age. Evaluation included measurement of albumin excretion in urine, immunoglobulin concentration, and lymphokine production in vitro, as well as analysis of T-cell receptor expression in splenic T-cell subsets and examination of renal histology by light and fluorescence microscopy. Results At 40 weeks of age, the serum level of IgA in these mice was substantially increased and the number of Vβ8⁺ CD4⁺splenic T-cells was significantly decreased compared with measurements in untreated controls. Both control and SEB-treated mice excreted less than 30 μg/mL of urinary albumin. In mice given SEB, the amount of interleukin 2 (IL-2) and tumor necrosis factor-α (T helper 1 [Th1]-type cytokines) produced by the in vitro-stimulated lymphocytes significantly decreased. whereas that of interleukin 4 (IL-4) and interleukin 6 (IL-6) (Th2-type cytokines) markedly increased compared with measurements in control mice. At 40 weeks of age, mice given SEB showed marked glomerular hypercellularity and enhanced glomerular C3 deposition by renal histology, compared with control mice. Conclusion These results suggest that bacterial superantigen SEB may modify glomerular lesions through activating Th2 cells, while inducing deletion of Th1 cells in this experimental model.     

Non-immune therapy of IgA glomerulonephritis

Summary: The involvement of the IgA immune system and complement components in IgA glomerulonephritis (IgAGN) has prompted the use of immunosuppressive drugs in therapy, but none has so far been shown to alter the natural course of the disease. Because most patients with IgAGN present during the chronic phase of their illness, at the time when the initiating immune events may no longer be active, nonimmune therapy which targets the common pathway of progressive renal injury is likely to be more useful. There is increasing evidence that angiotensin-converting enzyme inhibitors (ACEI) reduce proteinuria and renal injury in patients with IgAGN, and this effect may be observed in both normotensive and hypertensive patients. Yet to be determined is whether this effect is specific for ACEI and whatever other effective antihypertensive drugs may achieve a similar result. Fish oil has recently been shown to retard the progression of renal failure in patients with aggressive IgAGN, but a narrow therapeutic window appears to exist for this form of treatment. Antiplatelet agents on their own appear to be ineffective but in combination with anticoagulation (low dose warfarin) have been shown to have an antiproteinuric effect and may preserve renal function in patients with progressive disease. Future directions of non-immune therapy of IgAGN include evaluation of the renoprotective effect of angiotensin II receptor antagonists, free-radical scavengers and antilipid drugs. More work should also be done to identify factors which put the patients at risk of developing progressive disease and which predict therapeutic response, as has been done recently with the identification of the deletion polymorphism of the angiotensin-converting enzyme gene as a marker of progressive disease and therapeutic response to ACEI in patients with IgAGN.     

Mechanisms of proteinuria in nephrotic humans

The glomerular capillary wall imposes a remarkably efficient barrier to the passage of proteins the size of albumin and larger. The development of heavy proteinuria signifies impairment of the function of this barrier. Because endogenous proteins of graded size are heterogeneous with respect to their molecular charge and undergo extensive tubular reabsorption, they are not useful for quantifying the extent of barrier dysfunction. An alternative approach is to determine the fractional clearance of uncharged and non-reabsorbable polymers of graded size. When combined with a hydrodynamic theory of solute transport through a heteroporous membrane, the intrinsic properties of healthy and diseased glomerular capillary walls can be inferred. This approach reveals the nephrotic range proteinuria that attends minimal change nephropathy to be associated with impairment of both the size- and charge-selective properties of glomerular capillary walls.     

伊那普利治疗糖尿病肾病的临床研究

目的评估伊那普利治疗糖尿病肾病(DN)的临床疗效 ,并探讨其作用机制。方法40例持续微量蛋白尿的非胰岛素依赖型糖尿病(NIDDM)患者随机分为常规治疗组(n=19)和伊那普利治疗组(n=21)。利用 131I -邻碘马尿酸钠测定有效肾血浆流量(ERPF) ;肾小球滤过率(GFR)以内生肌酐清除率表示 ;通过ELISA法测定尿微量蛋白 ,包括白蛋白(ALB)、转铁蛋白(TF)、视黄醇结合蛋白(RBP)和N -乙酰 - β氨基葡萄糖苷酶(NAG)。结果伊那普利治疗组增高的尿ALB、TF、RBP和NAG均显著下降 ;ERPF显著增加 ;增加的滤过分数(FF)显著减低。而常规治疗组这些参数无显著变化。结论伊那普利具有改善DN患者的肾小球血流动力学 ,保护肾小球和肾小管功能的作用     

N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis.

The objectives of this study was to assess the overall effect of N-acetylcysteine (NAC) in preventing radiocontrast-induced nephropathy (RCIN) using all available data in the literature. RCIN is associated with increased morbidity and mortality. Existing randomized trials of NAC are small and show inconsistent results. Prior meta-analyses do not include data from the most current studies. We used standard search protocols to identify all published articles and abstracts of prospective trials using NAC with fluid hydration compared to hydration alone in patients with chronic renal insufficiency undergoing contrast procedures. A rise in serum creatinine by 0.5 mg/dl or 25% above baseline at 48-72 hr after contrast exposure was used as the primary outcome. We identified 14 trials of NAC with 1,584 patients published as full-text articles. Using a random-effects model, the use of oral NAC resulted in a significant reduction in the risk for developing RCIN (RR = 0.57; 95% CI = 0.37-0.84; P = 0.01). This finding did not significantly change in a fixed-effect model (RR = 0.55; 95% CI = 0.42-0.73) or when the data were reanalyzed using only randomized trials in all forms (i.e., articles and abstracts; RR = 0.67; 95% CI = 0.47-0.95). We identified only one important difference between the positive and the negative studies: the cumulative exposure to contrast media (174 vs. 152 ml). Metaregression did not show a significant relationship between contrast volume and the RR of developing RCIN (P > 0.10). In the trials showing benefit for NAC, the treated patients' postprocedure creatinine unexpectedly decreased by 0.21 mg/dl (95% CI = 0.33-0.08). Prophylaxis with NAC significantly reduces the risk for RCIN. The reasons for improvement in serum creatinine in patients treated with NAC are unclear, but may include improved renal blood flow due to NAC and/or vigorous hydration.     

尿蛋白-1与糖尿病肾病关系的研究

目的为了探讨尿蛋白-1(UP-)与糖尿病肾病的关系。方法用酶联免疫法测定了90例非胰岛素依赖型糖尿病(NIDDM)患者的UP-1,同时测定尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)、β2-微球蛋白(β2-mG)。结果糖尿病患者UP-1均较正常对照组增高,UP-1与尿A1b、尿NAG和β2-mG呈正相关。结论在糖尿病早期阶段,肾小管会受到损害,UP-1可作为诊断早期糖尿病肾病的敏感指标。     

P_(27)、PCNA与IgA肾病中医证型及病理类型的关系

目的 :运用免疫组化方法研究原发性IgA肾病患者肾组织中细胞周期调控蛋白P2 7(P2 7)、增殖细胞核抗原PCNA(PCNA)的表达 ,探讨两者与IgA肾病病理分级及其与中医证型之间的关系。 方法 :选择行肾穿刺活检的IgA肾病住院患者 5 2例 ,并按照中医辨证分型标准将其分为肺肾气虚证、脾肾阳虚证、肝肾阴虚证、气阴两虚证、血瘀证、湿热证六型。系膜增生的病理组织学分为 4级。运用免疫组化方法检测P2 7、PCNA的表达。结果 :(1)IgA肾病各个病理分级P2 7、PCNA的表达两两比较有统计学意义。显示随着系膜细胞增生的病理分级程度增高 ,PCNA的表达增高 ,而P2 7的表达则按相反方向进行。病理分级和P2 7、PCNA表达的等级相关性检验 (Spearman法 )显示 :P2 7的表达与病理类型呈非常显著负相关 ,而PCNA的表达与病理类型呈显著正相关。 (2 )IgA肾病三个中医证型的病理分级之间有统计学意义 ,其中气阴两虚证的病理分级比湿热证、肝肾阴虚证高 ,湿热证与肝肾阴虚证的病理分级之间无统计学意义。 (3)随着湿热→肝肾阴虚→气阴两虚的进展 ,P2 7的表达呈现出逐渐减少的趋势 ,而PCNA的表达呈现出逐渐增加的趋势。结论 :(1)P2 7、PCNA作为判断IgA肾病肾脏组织学损伤程度和预后的指标值得深入研究。 (2 )IgA肾病中医证型之间病理分     

背根神经节Nav1.8磷酸化在大鼠糖尿病痛性周围神经病变中的作用

目的 本研究采用射频热凝毁损腰交感神经节,探讨背根神经节（DRG）Nav1．8磷酸化在大鼠糖尿病痛性周围神经病变中的作用。方法 采用腹腔注射链尿佐菌素诱导糖尿病痛性周围神经病变大鼠模型,取造模成功的大鼠20只,随机分为糖尿病对照组（D组）及交感神经节射频热凝组（R组）,每组10只,另取10只同月龄大鼠为正常对照组（C组）。R组大鼠在X光机介导下行右侧L3,4椎旁腰交感神经节射频热凝毁损。分别于射频热凝前、射频热凝后1、2周时,采用von Frey纤维丝测定大鼠右侧后爪对机械性刺激缩足反应的阈值（PWT）;射频热凝后2周,采用Western-blotting方法测定DRG细胞Nav1．8蛋白和苏氨酸磷酸化Nav1．8蛋白表达,并采用透射电镜观察大鼠腓肠神经超微病理结构。结果 与C组比较,射频热凝前D组和R组PWT降低（P＜0．01）。射频热凝后1～2周,R组较D组PWT升高,但仍较C组降低（P＜0．05）。C组髓鞘排列均匀,轴突内可见形态正常的线粒体;D组脱髓鞘明显,髓鞘板层排列紊乱、断裂、肿胀;R组脱髓鞘程度明显减轻,髓鞘板层局部排列紊乱、空泡形成。与C组比较,D组和R组Nav1．8蛋白表达降低（P＜0．05）,而苏氨酸磷酸化Nav1．8蛋白表达增高（P＜0．01）;R组苏氨酸磷酸化Nav1．8蛋白表达低于D组（P＜0．05）。结论 DRG细胞Nav1．8的磷酸化可能是糖尿病痛性周围神经病变大鼠痛觉过敏形成的机制之一。     

p38丝裂原活化蛋白激酶在糖尿病大鼠神经病理性痛中的作用

目的探讨p38丝裂原活化蛋白激酶（p38MAPK）在链脲菌素诱导的糖尿病大鼠神经病理性痛中的作用。方法雌性Wistar大鼠31只，3月龄，体重180～220g，随机分为3组：对照组（C组，n=10）、糖尿病神经病理性痛组（D组，n=11）和p38MAPK抑制剂组（Ⅰ组，n=10）。D组、Ⅰ组单次腹腔注射链脲菌素65mg／kg制备糖尿病模型。糖尿病模型制备成功后，Ⅰ组尾静脉注射p38MAPK抑制剂SB203580 0．5mg／kg，1次／周，连续4周；C组和D组尾静脉注射等体积的生理盐水。给药4周后，测定机械缩足反应阈值（MWT）、左侧坐骨神经传导速率（NCV）、背根神经节（DRG）和脊髓的磷酸化p38MAPK水平。结果与C组比较，D组、Ⅰ组MWT下降，NCV减慢，伴有脱髓鞘现象，DRG和脊髓的磷酸化p38MAPK水平升高；与D组比较，Ⅰ组MWT升高，NCV增快，脱髓鞘程度减轻，DRG和脊髓的磷酸化p38MAPK水平下降。结论p38MAPK信号转导通路参与了糖尿病大鼠神经病理性痛的形成。